目的 探究定坤丹聯(lián)合戊酸雌二醇治療圍絕經(jīng)期綜合征的臨床療效。方法 選取2013年5月-2016年5月攀枝花市婦幼保健院接受診治的圍絕經(jīng)期綜合征患者82例，隨機(jī)分為對(duì)照組和治療組，每組各41例。對(duì)照組患者口服戊酸雌二醇片，2片/d，治療21 d為1個(gè)周期。治療組患者在對(duì)照組的基礎(chǔ)上口服定坤丹，每日早晚各1/2丸，連續(xù)3個(gè)月為1個(gè)療程。兩組均治療3個(gè)月。治療后，觀察兩組的臨床療效，并比較兩組卵泡刺激素（FSH）和雌二醇（E₂）水平，焦慮自評(píng)量表（SAS）、抑郁自評(píng)量表（SDS）、絕經(jīng)期生存質(zhì)量量表（MENQOL）和Greene更年期癥狀量表評(píng)分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為87.8%和97.6%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組FSH水平明顯降低，E₂水平顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組激素水平的改善明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組SAS、SDS、MENQOL和Greene評(píng)分均降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述量表評(píng)分明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 定坤丹聯(lián)合戊酸雌二醇治療圍絕經(jīng)期綜合征療效顯著，可維持圍絕經(jīng)期婦女正常的激素水平，減輕不良癥狀，具有一定的推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Dingkundan combined with estradiol valerate in treatment of perimenopause syndrome. Methods Patients (82 cases) with perimenopause syndrome in Panzhihua Women and Children's Hospital from May 2013 to May 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Estradiol Valerate Tablets, 2 tablets/d, and 21 d was one cycle. Patients in the treatment group were po administered with Dingkundan, 1/2 pill in the morning and evening. Three months were as one course. Two groups were both treated for 3 months. After treatment, the clinical efficacies were evaluated, and follicle stimulating hormone (FSH) and estradiol (E₂) levels, and self-rating anxiety scale (SAS), self-rating depression scale (SDS), menopause-specific quality of life questionnaire (MENQOL), and Greene menopausal symptoms scale in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 87.8% and 97.6%, respectively, and there was difference between two groups (P<0.05). After treatment, FSH level in two groups was significantly decreased, while E₂ level in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the hormone levels in the treatment group were improved more than those in the control group, with significant difference between two groups (P<0.05). After treatment, SAS, SDS, MENQOL, and Greene scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these scores in the treatment group were improved more than those in the control group, with significant difference between two groups (P<0.05). Conclusion Dingkundan combined with estradiol valerate has clinical curative effect in treatment of perimenopause syndrome, can maintain normal hormone levels in perimenopausal women and reduce adverse symptoms, which has a certain clinical application value.